ArticleClinical oral investigations2026
Network pharmacology, molecular docking, and experimental validation of the mechanisms of Withaferin a in treating periodontitis.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the function and therapeutic mechanism of Withaferin A (WFA) in treatment of periodontitis using network pharmacology analysis and experiment validation.
methodsThe optimal concentration of WFA was determined using CCK-8 assay. IL-6 and IL-1β protein levels were measured by ELISA. Osteogenic differentiation under inflammation was evaluated via ALP staining and activity, Alizarin Red staining, and mineralization quantification. Expression of osteogenic markers (RUNX2, OCN, ALP) was analyzed by Western blot and RT-qPCR. Network pharmacology and molecular docking were used to predict and validate WFA targets, followed by experimental verification with WB and RT-qPCR. Mitochondrial status was examined using JC-1 staining and TEM, while ROS levels were detected to assess oxidative stress. Expression of SLC7A11, GPX4, and OPA1 was measured by WB and RT-qPCR. WFA's therapeutic effect was further validated in a ligature-induced periodontitis (LIP) rat model using micro-CT, H&E staining, and immunohistochemistry.
resultsOur study demonstrated that WFA exerts multi-faceted therapeutic effects on periodontitis. It promoted osteogenesis by upregulating osteogenic markers (RUNX2, OCN, ALP) and counteracted Pg-LPS-induced inflammation, reducing IL-6 and IL-1β levels and attenuating bone resorption in vitro. Bioinformatics analysis identified 119 potential targets of WFA, with 100 overlapping periodontitis-related genes. GO and KEGG enrichment highlighted the AGE-RAGE, IL-17, and Relaxin signaling pathways. Molecular docking confirmed strong binding of WFA to JUN, FN1, and TGFβ, which were functionally validated. Mechanistically, WFA reduced ROS, preserved mitochondrial integrity, and upregulated SLC7A11 and GPX4, indicating anti-ferroptotic effects via the SLC7A11/GPX4 axis. In vivo, WFA alleviated Pg-LPS-induced bone loss.
conclusionIn conclusion, WFA exhibits therapeutic potential in periodontitis through suppressing ferroptosis via SLC7A11/GPX4 axis, which promotes osteogenesis and inhibits Pg-LPS-induced inflammation. CLINICAL RELEVANCE: WFA demonstrates significant potential as a therapeutic intervention for periodontitis.
Indexed as
Identifiers
42714624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.